@article{f0bb13a422ee43e197f83d82c75f733b,
title = "Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland",
abstract = "Multiple studies implicate heterozygous GBA mutations as a major genetic risk factor for Parkinson's disease (PD); however, the frequency of mutations has never been examined in PD patients from the Irish population. We prospectively recruited 314 unrelated Irish PD patients (UK Brain Bank Criteria) and 96 Irish healthy controls (without any signs or family history of parkinsonism) attending. The Dublin Neurological Institute (DNI). Complete exon GBA Sanger sequencing analysis with flanking intronic regions was performed. The GBA carrier frequency was 8.3% in PD and 3.1% in controls. We identified a number of potentially pathogenic mutations including a p.G195E substitution and a p.G377C variant, previously described in a case study of Gaucher's disease in Ireland. On genotype–phenotype assessment hallucinations, dyskinesia, and dystonia were more prevalent in GBA-PD. The genetic etiology of PD in Ireland differs from the continental Europe as seen with the lower LRRK2 and higher than in most European countries GBA mutation frequency. Determining genetic risk factors in different ethnicities will be critical for future personalized therapeutic approach.",
keywords = "GBA, Ireland, Parkinson's disease, glucocerebrosidase, sequencing",
author = "Olszewska, {Diana A.} and Allan McCarthy and Soto-Beasley, {Alexandra I.} and Walton, {Ronald L.} and Brian Magennis and McLaughlin, {Russell L.} and Orla Hardiman and Ross, {Owen A.} and Tim Lynch",
note = "Funding Information: The authors would like to thank the Genome Aggregation Database (gnomAD) and the groups that provided exome and genome variant data to this resource. A full list of contributing groups can be found at http://gnomad.broadinstitute.org/about. The authors would like to acknowledge the statistical advice obtained from Dr. Ricardo Segurado, UCD CSTAR. Funding. RM was supported by the MND Association of England, Wales and Northern Ireland (957-799), and OH was supported by Science Foundation Ireland (15/SPP/3244). Mayo Clinic is an American Parkinson Disease Association (APDA) Mayo Clinic Information and Referral Center, an APDA Center for Advanced Research and the Mayo Clinic Lewy Body Dementia Association (LBDA) Research Center of Excellence. OR was supported by the National Institutes of Health (NIH; R01 NS78086, U54 NS100693, U54 NS110435), the US Department of Defense (W81XWH-17-1-0249), The Little Family Foundation, the Mayo Clinic Center for Individualized Medicine, and the Michael J. Fox Foundation. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Olszewska, McCarthy, Soto-Beasley, Walton, Magennis, McLaughlin, Hardiman, Ross and Lynch.",
year = "2020",
month = jun,
day = "30",
doi = "10.3389/fneur.2020.00527",
language = "English (US)",
volume = "11",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
}